BioNTech SE (BNTX) Teams Up with BMS in $11B Cancer Deal

We recently published 11 Best Cancer Stocks to Buy Right Now. BioNTech SE is one of them.

BioNTech SE (NASDAQ:BNTX), a German biotechnology company, specializes in mRNA-based immunotherapies for cancer and infectious diseases and stands eleventh on our list among the best cancer stocks. Following its global recognition for the COVID-19 vaccine, the company has been expanding its oncology pipeline with personalized cancer immunotherapies, next-generation immunomodulators, and targeted therapies.

In June 2025, BioNTech SE (NASDAQ:BNTX) entered a global collaboration with Bristol Myers Squibb (BMS) to co-develop and commercialize BNT327, a bispecific antibody targeting PD-L1 and VEGF-A across multiple solid tumors. The deal, worth up to $11.1 billion, underscores the business’s commitment to advancing oncology beyond its COVID-19 vaccine success.

BioNTech SE (NASDAQ:BNTX) also announced the acquisition of CureVac, a company with proprietary mRNA technology. The company has initiated multiple Phase 1/2 clinical trials with BNT327 and other novel mRNA and antibody-drug conjugate candidates, focusing on combination therapies for breast, lung, colorectal, and other solid tumors. These trials aim to validate synergistic approaches targeting multiple tumor-specific pathways.

While we acknowledge the potential of BNTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.